Bibek Aryal, Surgeon-Scientist, Independent Researcher in Cancer Outcomes, shared a post on LinkedIn:
“New in Nature Reviews Clinical Oncology: Dario Trapani and I argue that a treatment can have patient value, yet remain clinically orphaned when it lacks patent value.
Our new Comment ‘Patient value over patent value: the mandate for open-source oncology‘, addresses a structural failure in the pharmaceutical ecosystem.
Clinical value should not depend on commercial ownership. This is not an argument against pharmaceutical innovation.
It is an argument for completing the innovation system – so that treatments are judged by the benefit they can deliver to patients, not only by the commercial rights attached to them.
To address this structural gap, we outline the mandate for an open-source oncology framework.
The question we raise is simple: What would it take for health systems to evaluate “ownerless” therapies with the same rigour as patented drugs?”
Title: Patient value over patent value: the mandate for open-source oncology
Authors: Bibek Aryal and Dario Trapani
Read The Full Article
Other articles featuring Bibek Aryal and Dario Trapani on OncoDaily.